HEALTH● LOW1d ago · Sep 13, 2026, 5:23 PM
Summit’s ivonescimab cuts death risk by 27% versus Keytruda in lung cancer trial
Seeking Alpha Tech · global
A clinical trial shows Summit's drug, ivonescimab, reduced the risk of death by 27% compared to Keytruda in lung cancer patients. This represents a potentially important advancement in lung cancer treatment.
GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.
More in Health
HEALTH42m ago3rd person with measles dies in PennsylvaniaCBS NewsHEALTH56m agoChile validated as first South American country to eliminate dog-transmitted rabiesABC NewsHEALTH2h ago97% of PHCs in 16 states fail national staffing standards – ReportPremium TimesHEALTH2h agoPennsylvania woman dies of measles complications, coroner reportsCBS News